Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer

被引:92
|
作者
Saint, F [1 ]
Patard, JJ
Maille, P
Soyeux, P
Hoznek, A
Salomon, L
Abbou, CC
Chopin, DK
机构
[1] Hop Henri Mondor, Dept Urol, Grp Etud Tumeurs Urol, F-94010 Creteil, France
[2] Hop Henri Mondor, EMI 99 09, INSERM, Dept Urol, F-94010 Creteil, France
来源
JOURNAL OF UROLOGY | 2002年 / 167卷 / 01期
关键词
bladder; bladder neoplasms; Mycobacterium bovis; cytokines; interleukin-2;
D O I
10.1016/S0022-5347(05)65469-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Interleukin (IL)-2 and interferon-gamma are released during T helper 1 lymphocyte responses, while IL-10 is released during T helper 2 responses. We evaluated the prognostic value of urinary IL-2, interferon-gamma and IL-10 levels in patients with superficial bladder cancer treated with bacillus Calmette-Guerin (BCG) instillation Methods: Urinary IL-2, interferon-gamma and IL-10 were measured by enzyme-linked immunosorbent assay in 37 patients receiving BCG for stages Ta/T1 superficial bladder cancer, and carcinoma in situ. Measurements were made after instillations 5 and 6 during a course of 6 weekly instillations of 150 mg. BCG, Pasteur strain. Correlations of cytokine levels with the clinical outcome were evaluated using the log rank test Results: Median followup was 29 months. Patients with urinary IL-2 less than 27 pg./mu mol. creatinine were significantly more likely to have recurrences than those with higher values (log rank test p = 0.0009). Urinary IL-10 and interferon-gamma levels had no apparent impact on the risk of recurrence or progression Conclusion: Urinary IL-2 levels may serve to identify patients at risk for bladder cancer recurrence after a single course of BCG and, thus, to tailor individual treatment.
引用
下载
收藏
页码:364 / 367
页数:4
相关论文
共 50 条
  • [1] Intravesical bacillus Calmette-Guerin therapy for T1 superficial bladder cancer
    Demkow, Tomasz
    Alter, Andrzej
    Wiechno, Pawel
    UROLOGIA INTERNATIONALIS, 2008, 80 (01) : 74 - 79
  • [2] Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value
    DeReijke, TM
    DeBoer, EC
    Kurth, KH
    Schamhart, DHJ
    JOURNAL OF UROLOGY, 1996, 155 (02): : 477 - 482
  • [3] INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR SUPERFICIAL BLADDER-CANCER - EFFECT OF BACILLUS CALMETTE-GUERIN VIABILITY ON TREATMENT RESULTS
    KELLEY, DR
    RATLIFF, TL
    CATALONA, WJ
    SHAPIRO, A
    LAGE, JM
    BAUER, WC
    HAAFF, EO
    DRESNER, SM
    JOURNAL OF UROLOGY, 1985, 134 (01): : 48 - 53
  • [4] Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value - Reply
    deReijke, TM
    deBoer, EC
    Kurth, KH
    Schamhart, DHJ
    JOURNAL OF UROLOGY, 1996, 155 (02): : 482 - 482
  • [5] INTRAVESICAL BACILLUS CALMETTE-GUERIN TREATMENT FOR SUPERFICIAL BLADDER-TUMORS
    SHINKA, T
    HIRANO, A
    UEKADO, Y
    KYOKU, I
    AOSHI, H
    OHKAWA, T
    BRITISH JOURNAL OF UROLOGY, 1989, 63 (06): : 610 - 615
  • [6] PROSPECTIVE RANDOMIZED COMPARISON OF INTRAVESICAL WITH PERCUTANEOUS BACILLUS CALMETTE-GUERIN VERSUS INTRAVESICAL BACILLUS CALMETTE-GUERIN IN SUPERFICIAL BLADDER-CANCER
    LAMM, DL
    DEHAVEN, JI
    SHRIVER, J
    SAROSDY, MF
    JOURNAL OF UROLOGY, 1991, 145 (04): : 738 - 740
  • [7] Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: Study of the mechanism of bacillus Calmette-Guerin immunotherapy
    Shintani, Yasuyo
    Sawada, Yoshihisa
    Inagaki, Takeshi
    Kohjimoto, Yasuo
    Uekado, Yasunari
    Shinka, Toshiaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2007, 14 (02) : 140 - 146
  • [8] Intravesical Gemcitabine for Treatment of Superficial Bladder Cancer not Responding to Bacillus Calmette-Guerin Vaccine
    Elkoushy, M. A.
    AFRICAN JOURNAL OF UROLOGY, 2010, 16 (04) : 110 - 116
  • [9] Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer
    Danisman, A
    Bulut, K
    Kukul, E
    Özen, I
    Sevük, M
    UROLOGIA INTERNATIONALIS, 2000, 64 (04) : 198 - 201
  • [10] PROGNOSTIC FACTORS IN PATIENTS TREATED WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR SUPERFICIAL BLADDER-CANCER
    TORRENCE, RJ
    KAVOUSSI, LR
    CATALONA, WJ
    RATLIFF, TL
    JOURNAL OF UROLOGY, 1988, 139 (05): : 941 - 944